tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Aspire Biopharma Faces Nasdaq Delisting Notice

Story Highlights
Aspire Biopharma Faces Nasdaq Delisting Notice

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Aspire Biopharma Holdings ( (ASBP) ) is now available.

Aspire Biopharma Holdings, Inc. received notifications from Nasdaq on April 16, 2025, regarding noncompliance with listing rules due to its market value and bid price falling below required levels for 30 consecutive days. The company failed to rectify these deficiencies within the given 180-day compliance period, leading to a potential delisting notice on October 15, 2025. Aspire Biopharma has requested a hearing to present its compliance plan and seek an extension, although there is no guarantee of success.

More about Aspire Biopharma Holdings

Aspire Biopharma Holdings, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapies.

Average Trading Volume: 21,977,383

Technical Sentiment Signal: Sell

Current Market Cap: $15.82M

Find detailed analytics on ASBP stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1